• 1. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 2. Aggregation-induced emission based on a fluorinated macrocycle: visualizing spontaneous and ultrafast solid-state molecular motions at room temperature via F?F interactions?
  Mei Zhang,Jingjing Guo,Tingting Liu,Zhanyu He,Majeed Irfan,Zujin Zhao,Zhuo Zeng J. Mater. Chem. C, 2020,8, 14919-14924
• 3. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
• 4. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 5. An autoreduction method to prepare plasmonic gold-embedded polypeptide micelles for synergistic chemo-photothermal therapy?
  Xingjie Wu,Linzhu Zhou,Yue Su,Chang-Ming Dong J. Mater. Chem. B, 2016,4, 2142-2152

Introduction to 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylmethanamine (CAS No. 1976012-69-7)

5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylmethanamine, identified by its CAS number 1976012-69-7, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of borylated pyridine derivatives, which are widely recognized for their versatile applications in drug discovery and development. The unique structural features of this molecule, particularly the presence of a tetramethyl-1,3,2-dioxaborolan-2-yl substituent, make it a valuable intermediate in cross-coupling reactions, which are pivotal in constructing complex molecular architectures essential for novel therapeutic agents.

The pyridin-3-ylmethanamine core of the compound contributes to its potential biological activity by providing a scaffold that can interact with various biological targets. Pyridine derivatives are well-documented for their role in modulating enzyme function and receptor binding, making them indispensable in the design of small-molecule drugs. The borylated moiety further enhances the compound's utility by enabling palladium-catalyzed coupling reactions, such as Suzuki-Miyaura couplings, which are widely employed in the synthesis of biaryl compounds—a common motif in many pharmacologically active molecules.

Recent advancements in synthetic methodologies have highlighted the importance of boron-containing compounds like 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylmethanamine in the development of next-generation therapeutics. For instance, studies have demonstrated that borylated pyridines can serve as effective substrates for the construction of highly functionalized heterocycles, which are often associated with enhanced pharmacological properties. The stability and reactivity of the tetramethyl-1,3,2-dioxaborolan-2-yl group under various reaction conditions have made it a preferred choice for medicinal chemists seeking to streamline synthetic routes while maintaining high yields and purity.

In the context of drug discovery, 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylmethanamine has been explored as a key building block in the synthesis of inhibitors targeting inflammatory pathways. Pyridine-based inhibitors have shown promise in preclinical studies for their ability to modulate key enzymes involved in processes such as pain perception and immune response. The incorporation of a boryl group not only facilitates further functionalization but also enhances metabolic stability, which is a critical factor in drug development. By leveraging modern catalytic systems, researchers can efficiently derivatize this compound to generate libraries of analogs with tailored biological activities.

The compound's potential extends beyond its role as a synthetic intermediate; it also exhibits interesting physicochemical properties that make it suitable for formulation into drug products. For example, its solubility profile and thermal stability can be optimized through structural modifications derived from this core scaffold. Such properties are essential for ensuring adequate bioavailability and shelf-life of pharmaceutical formulations. Additionally, computational studies have suggested that variations in the substitution pattern around the pyridine ring can influence electronic distributions, thereby affecting binding affinity to biological targets—a crucial consideration in rational drug design.

Current research trends indicate that 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylmethanamine may find utility in emerging therapeutic areas such as oncology and neurology. In oncology research, borylated pyridines have been investigated for their ability to interfere with signaling pathways that drive tumor growth and metastasis. The versatility of this compound allows for the facile introduction of diverse functional groups that can fine-tune its interaction with disease-specific biomarkers. Similarly, in neurodegenerative disease models, pyridine derivatives have demonstrated potential as cholinesterase inhibitors or NMDA receptor modulators—targets implicated in conditions such as Alzheimer's disease and Parkinson's disease.

The synthesis and application of 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylenathanamine also align with green chemistry principles by promoting efficient and sustainable chemical transformations. The use of boronic acids and esters in cross-coupling reactions is favored over traditional methods due to reduced waste generation and milder reaction conditions. This aligns with global efforts to minimize environmental impact while maximizing synthetic efficiency—a cornerstone of modern pharmaceutical research. Furthermore, advances in flow chemistry have enabled scalable production of this compound under controlled conditions, further enhancing its practicality for industrial applications.

As computational chemistry plays an increasingly pivotal role in drug discovery, 5-(tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) py ridin - 3 - ylmethanamine has been subjected to rigorous virtual screening protocols to identify novel therapeutic candidates. Molecular docking studies have revealed its potential binding affinity to various protein targets by exploiting hydrogen bonding networks and hydrophobic interactions facilitated by its dual aryl-amino structure. Such insights guide experimental efforts toward optimizing lead compounds derived from this scaffold—a testament to interdisciplinary collaboration between experimentalists and computational scientists.

The future prospects for this compound remain promising as new synthetic strategies continue to emerge alongside expanding knowledge about their biological roles . Continued exploration into derivatives will likely uncover additional applications , reinforcing its significance within medicinal chemistry . Whether used as an intermediate or standalone agent , 5-( tet ram ethyl - 1 , 3 , 2 - dioxabor lan - 2 - yl ) py ridin - 3 - ylmeth an am ine ( CAS No . 1976012 -69 -7) stands at forefront innovation , bridging gaps between academic discovery industry translation . Its unique combination structural features functionality positions it cornerstone ongoing advancements pharmaceutical sciences .

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)